Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

4(50%)

Results Posted

33%(1 trials)

Phase Distribution

Ph phase_1

13%

Ph phase_2

25%

Ph not_applicable

38%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

1(16.7%)

Phase 2Efficacy & side effects

2(33.3%)

N/ANon-phased studies

3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(3)

Detailed Status

Recruiting4

Completed3

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (16.7%)

Phase 22 (33.3%)

N/A3 (50.0%)

Trials by Status

completed338%

not_yet_recruiting113%

recruiting450%

Recent Activity

4 active trials

Showing 5 of 8

completedphase_2

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

NCT03623373

recruitingphase_2

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

NCT06738368

recruitingnot_applicable

Marrow Cellution™ vs. Traditional BMA Harvest Project

NCT06388993

not_yet_recruitingnot_applicable

Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms

NCT07094750

recruitingnot_applicable

Hematopoietic Stem Cell Dysfunction in the Elderly After Severe Injury

NCT02577731

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT03623373Phase 2

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Completed

NCT06738368Phase 2

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Recruiting

NCT06388993Not Applicable

Marrow Cellution™ vs. Traditional BMA Harvest Project

Recruiting

NCT07094750Not Applicable

Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms

Not Yet Recruiting

NCT02577731Not Applicable

Hematopoietic Stem Cell Dysfunction in the Elderly After Severe Injury

Recruiting

NCT06701214

The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository